HIKAL vs NATCOPHARM: Stock Comparison
NATCO PHARMA is the larger company by market capitalisation. HIKAL shows a lower P/E and faster revenue growth, while NATCO PHARMA shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HIKAL leads 3; NATCOPHARM leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HIKAL | NATCOPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | HIKAL | NATCOPHARM |
|---|---|---|
| Live Price | ₹203.18 | ₹785.15 |
| Day Change | -3.6% | 0.09% |
| Volume | 3.29 L | 7 L |
| 52-Week High | ₹261 | ₹1,226.8 |
| 52-Week Low | ₹146.25 | ₹779 |
| Distance from 52W High | -22.15% | -36% |
Valuation
| Metric | HIKAL | NATCOPHARM |
|---|---|---|
| Market Cap | ₹2,501 Cr | ₹15,478 Cr |
| P/E Ratio | 0x | 13.53x |
| P/B Ratio | 2.09x | 1.68x |
| EPS | ₹-0.6 | ₹11.53 |
| Book Value | ₹97.23 | ₹514.83 |
| Dividend Yield | 0.28% | 0.57% |
Growth
| Metric | HIKAL | NATCOPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 37.3% | -39.6% |
| EPS Growth (TTM YoY) | 68.3% | -34.1% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | HIKAL | NATCOPHARM |
|---|---|---|
| ROE | -4.07% | 14.98% |
| ROCE | -0.87% | 14.19% |
| Net Margin | -2.88% | 34.78% |
| Operating Margin | -0.95% | 38.85% |
| Debt to Equity | 0.57x | 0.08x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | HIKAL | NATCOPHARM |
|---|---|---|
| Promoter Holding | 68.85% | 49.12%▼ 0.02 pp |
| FII Holding | 1.27%▲ 0.28 pp | 16%▼ 0.99 pp |
| DII Holding | 5.32%▼ 1.92 pp | 6.16%▲ 0.54 pp |
| Public Holding | 24.56%▲ 1.63 pp | 28.45%▲ 0.48 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HIKAL and NATCO PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.